Hematologists and oncologists from UC San Francisco shared research results and clinical guidance at the world’s premier meeting for malignant and non-malignant hematology at the American Society of ...

The waveLINE-003 trial demonstrates the efficacy of zilovertamab vedotin combined with standard therapy, with manageable safety profiles in difficult-to-treat DLBCL patients. ADCs provide logistical ...

Findings from the phase 1/2 BRUIN study (NCT03740529) show that pirtobrutinib (Jaypirca), a Bruton tyrosine kinase inhibitor (BTKi), monotherapy offers promising clinical efficacy and a favorable ...

Seven Republican-led states have banned the manufacture, sale or distribution of lab-grown meat – with the backing of RFK Jr.

Key Takeaways. TTP following R-CHOP is a strong prognostic factor for survival in R/R DLBCL, with shorter TTP linked to ...

Beam Therapeutics (NASDAQ:BEAM) is one of the most promising mid-cap healthcare stocks under $50. On December 9, H.C. Wainwright analyst Patrick Trucchio reaffirmed his bullish stance on Beam ...

Clinicians from Fox Chase Cancer Center at Temple University Health share their highlights from the Society of Urologic ...

When you take a drug, where in your body does it actually go? For most medications, scientists can make only educated guesses about the ...

Those at the 10th Place apartments in Southeast Washington said the president’s crime strategy deepened their distrust of ...

CytomX Therapeutics, Inc. (NASDAQ:CTMX), a clinical-stage oncology company, develops conditionally activated biologics ...

All year long, these moments captivated the public, demonstrated dangerous trends, and pushed research and innovation forward ...

This plant root was among those studied as part of new research exploring the molecular underpinnings of how plants twist ...